Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer
Study on Human Epidermal Growth Factor 2 (Her2) Expression Changes in Human Breast Cancer After Radiotherapy
Sponsor: Qingdao Central Hospital
This observational or N/A phase trial investigates Human Epidermal Growth Factor 2 Negative Carcinoma of Breast and is currently completed. Qingdao Central Hospital leads this study, which shows 9 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Apr 2023 — Jul 2024 [monthly]
Completed
Status: Suspended → Completed
-
Jan 2021 — Apr 2023 [monthly]
Suspended
-
Jun 2018 — Jan 2021 [monthly]
Suspended
▶ Show 4 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Suspended
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Suspended NA
Status: Unknown Status → Suspended
-
Oct 2017 — Mar 2018 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2017 — Oct 2017 [monthly]
Recruiting NA
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Qingdao Central Hospital
For direct contact, visit the study record on ClinicalTrials.gov .